Home News About Us Contact Contributors Disclaimer Privacy Policy Help FAQ

Home
Search
Quick Search
Advanced
Fulltext
Browse
Collections
Persons
My eDoc
Session History
Login
Name:
Password:
Documentation
Help
Support Wiki
Direct access to
document ID:


          Institute: MPI für Evolutionsbiologie     Collection: Evolutionary ecology     Display Documents



  history
ID: 478377.0, MPI für Evolutionsbiologie / Evolutionary ecology
Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells.
Authors:Lenaerts, Tom; Pacheco, Jorge M.; Traulsen, Arne; Dingli, David
Language:English
Date of Publication (YYYY-MM-DD):2010-06
Title of Journal:Haematologica
Volume:95
Issue / Number:6
Start Page:900
End Page:907
Review Status:not specified
Audience:Not Specified
Abstract / Description:BACKGROUND: Tyrosine kinase inhibitors, such as imatinib, are not considered curative for chronic myeloid leukemia--regardless of the significant reduction of disease burden during treatment--since they do not affect the leukemic stem cells. However, the stochastic nature of hematopoiesis and recent clinical observations suggest that this view must be revisited. DESIGN AND METHODS: We studied the natural history of a large cohort of virtual patients with chronic myeloid leukemia under tyrosine kinase inhibitor therapy using a computational model of hematopoiesis and chronic myeloid leukemia that takes into account stochastic dynamics within the hematopoietic stem and early progenitor cell pool. RESULTS: We found that in the overwhelming majority of patients the leukemic stem cell population undergoes extinction before disease diagnosis. Hence leukemic progenitors, susceptible to tyrosine kinase inhibitor attack, are the natural target for chronic myeloid leukemia treatment. Response dynamics predicted by the model closely match data from clinical trials. We further predicted that early diagnosis together with administration of tyrosine kinase inhibitor opens the path to eradication of chronic myeloid leukemia, leading to the wash out of the aberrant progenitor cells, ameliorating the patient's condition while lowering the risk of blast transformation and drug resistance. CONCLUSIONS: Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia, although it may have to be prolonged. The depth of response increases with time in the vast majority of patients. These results illustrate the importance of stochastic effects on the dynamics of acquired hematopoietic stem cell disorders and have direct relevance for other hematopoietic stem cell-derived diseases.
Free Keywords:chronic myeloid leukemia; tyrosine kinase inhibitors; cure; stochastic dynamics
External Publication Status:published
Document Type:Article
Affiliations:MPI für Evolutionsbiologie/Abt. Evolutionsökologie
MPI für Evolutionsbiologie/AG Evolutionstheorie
External Affiliations:MLG, Departement d'Informatique, Universite Libre de Bruxelles, Brussels, Belgium; Departamento de Matemática da Universidade do Minho, Braga, Portugal; ATP-group, CFTC, Complexo Interdisciplinar, Lisboa, Portugal; Division of hematology, Mayo Clinic College of Medicine, Rochester, MN, USA
Identifiers:ISSN:0390-6078 (print) [ID-No:1]
ISSN:1592-8721 (online) [ID-No:2]
DOI:10.3324/haematol.2009.015271 [ID-No:3]
LOCALID:2765/S 39097 [Listen-Nummer/S-Nummer]
Full Text:
You have privileges to view the following file(s):
Lenaerts_2010.pdf  [904,00 Kb]   
 
The scope and number of records on eDoc is subject to the collection policies defined by each institute - see "info" button in the collection browse view.